These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 21510895)

  • 21. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder.
    Handen BL; Johnson CR; Lubetsky M
    J Autism Dev Disord; 2000 Jun; 30(3):245-55. PubMed ID: 11055460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Short-Term Placebo Response in Children With Attention-Deficit Hyperactivity Disorder (ADHD).
    Cohen A; Plonsky-Toder M; Tirosh E
    J Child Neurol; 2018 Apr; 33(5):340-346. PubMed ID: 29451082
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability.
    Simonoff E; Taylor E; Baird G; Bernard S; Chadwick O; Liang H; Whitwell S; Riemer K; Sharma K; Sharma SP; Wood N; Kelly J; Golaszewski A; Kennedy J; Rodney L; West N; Walwyn R; Jichi F
    J Child Psychol Psychiatry; 2013 May; 54(5):527-35. PubMed ID: 22676856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Minimizing adverse events while maintaining clinical improvement in a pediatric attention-deficit/hyperactivity disorder crossover trial with dextroamphetamine and methylphenidate.
    Ramtvedt BE; Aabech HS; Sundet K
    J Child Adolesc Psychopharmacol; 2014 Apr; 24(3):130-9. PubMed ID: 24666268
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional improvement and correlations with symptomatic improvement in adults with attention deficit hyperactivity disorder receiving long-acting methylphenidate.
    Buitelaar JK; Casas M; Philipsen A; Kooij JJ; Ramos-Quiroga JA; Dejonckheere J; van Oene JC; Schäuble B
    Psychol Med; 2012 Jan; 42(1):195-204. PubMed ID: 21733214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacogenetics of methylphenidate response in preschoolers with ADHD.
    McGOUGH J; McCRACKEN J; Swanson J; Riddle M; Kollins S; Greenhill L; Abikoff H; Davies M; Chuang S; Wigal T; Wigal S; Posner K; Skrobala A; Kastelic E; Ghuman J; Cunningham C; Shigawa S; Moyzis R; Vitiello B
    J Am Acad Child Adolesc Psychiatry; 2006 Nov; 45(11):1314-1322. PubMed ID: 17023870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
    Shang CY; Pan YL; Lin HY; Huang LW; Gau SS
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Titration Study of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR) in Preschool Children with Attention-Deficit/Hyperactivity Disorder.
    Childress AC; Kollins SH; Foehl HC; Newcorn JH; Mattingly G; Kupper RJ; Adjei AL
    J Child Adolesc Psychopharmacol; 2020 Mar; 30(2):58-68. PubMed ID: 32125903
    [No Abstract]   [Full Text] [Related]  

  • 30. Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes.
    Palumbo DR; Sallee FR; Pelham WE; Bukstein OG; Daviss WB; McDERMOTT MP;
    J Am Acad Child Adolesc Psychiatry; 2008 Feb; 47(2):180-188. PubMed ID: 18182963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Child and parent perceptions of stimulant medication treatment in attention deficit hyperactivity disorder.
    Efron D; Jarman FC; Barker MJ
    J Paediatr Child Health; 1998 Jun; 34(3):288-92. PubMed ID: 9633980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Factors affecting therapeutic effect of ADHD treated by optimal dose of methylphenidate].
    Yang L; Wang YF
    Beijing Da Xue Xue Bao Yi Xue Ban; 2007 Jun; 39(3):284-8. PubMed ID: 17572785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of OROS methylphenidate on encopresis in children with attention-deficit/hyperactivity disorder.
    Yılmaz S; Bilgiç A; Hergüner S
    J Child Adolesc Psychopharmacol; 2014 Apr; 24(3):158-60. PubMed ID: 24168715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of methylphenidate on leptin and appetite in children with attention-deficit hyperactivity disorder: an open label trial.
    Işeri E; Kiliç BG; Senol S; Karabacak NI
    Methods Find Exp Clin Pharmacol; 2007; 29(1):47-52. PubMed ID: 17344944
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect.
    Brams M; Muniz R; Childress A; Giblin J; Mao A; Turnbow J; Borrello M; McCague K; Lopez FA; Silva R
    CNS Drugs; 2008; 22(8):693-704. PubMed ID: 18601306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reboxetine for ADHD in children non-responders or with poor tolerance to methylphenidate: a prospective long-term open-label study.
    Quintero J; López-Muñoz F; Alamo C; Loro M; García-Campos N
    Atten Defic Hyperact Disord; 2010 Nov; 2(3):107-13. PubMed ID: 21432596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anxiety and methylphenidate in attention deficit hyperactivity disorder: a double-blind placebo-drug trial.
    Moshe K; Karni A; Tirosh E
    Atten Defic Hyperact Disord; 2012 Sep; 4(3):153-8. PubMed ID: 22622628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
    Coghill D; Banaschewski T; Lecendreux M; Soutullo C; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Lyne A; Squires L
    Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of osmotic-release oral system (OROS) methylphenidate for mothers with attention-deficit/hyperactivity disorder (ADHD): preliminary report of effects on ADHD symptoms and parenting.
    Chronis-Tuscano A; Seymour KE; Stein MA; Jones HA; Jiles CD; Rooney ME; Conlon CJ; Efron LA; Wagner SA; Pian J; Robb AS
    J Clin Psychiatry; 2008 Dec; 69(12):1938-47. PubMed ID: 19192455
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Open-label use of placebos in the treatment of ADHD: a pilot study.
    Sandler AD; Bodfish JW
    Child Care Health Dev; 2008 Jan; 34(1):104-10. PubMed ID: 18171451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.